摘要
目的:探讨不同剂量阿托伐他汀对老年冠心病患者经皮冠状动脉介入治疗(PCI)后再狭窄及炎症因子的影响。方法:选择2015年5月—2017年6月在本院择期行PCI治疗的老年冠心病患者94例为研究对象,随机分为小剂量组和大剂量组,每组47例。小剂量组口服阿托伐他汀20mg/次,1次/d;大剂量组口服阿托伐他汀40mg/次,1次/d。用药7d后行PCI术,术后维持用药6个月。术后随访12个月,比较两组术后再狭窄率、心血管事件发生率以及血清炎症因子水平。结果:术后6个月,大剂量组患者血清hs-CPR、IL-6和TNF-α水平显著低于小剂量组,差异有统计学意义(P <0. 05)。术后随访12个月,大剂量组患者PCI术后再狭窄以及总的不良心血管事件发生率显著低于小剂量组,差异有统计学意义(P <0. 05)。两组患者不良反应发生率比较差异无统计学意义(P> 0. 05)。结论:大剂量阿托伐他汀可以有效降低老年冠心病患者PCI术后血清炎症因子水平,减少术后再狭窄和总的不良心血管事件发生率。
Objective ：To investigate the effect of different doses of atorvastatin on restenosis and inflammatory factors in elderly coronary heart disease patients undergoing percutaneous coronary intervention. Methods：94 cases of elderly coronary heart disease patients undergoing percutaneous coronary intervention in our hospital from May 2015 to June 2017 were selected and randomly assigned inlo low-dose group and high-dose group with 47 patients in each group. Patients in the small dose group were treated with atorvastatin, 20mg/time, once a day, while the high-dose group was treated with atorvastatin,40mg/ time, once a day. 7 days after treatment, PCI was performed in all patients. Postoperative maintenance medication for 6 months. All patients were followed up for 12 months, the restenosis rate, cardiovascular events and serum inflammatory factors were compared between the two groups. Results：6 months after operation, the hs-CPR, IL-6 and TNF-α levels in the high- dose group were significantly lower than those in the low-dose group, the difference was statistically significant （ P 〈 0.05 ）. After 12 months of follow-up, the incidence of restenosis and totally adverse cardiovascular events after PCI in high-dose group were significantly lower than that in low-dose group, the difference was statistically significant （P 〈 0.05）. There was no significant difference in adverse reactions between the two groups （ P 〉 0.05 ）. Conclusion ： High dose atorvastatin can effectively reduce the inflammatory factors in elderly coronary heart disease patients after PCI, reduce postoperative restenosis and totally adverse cardiovascular events.
作者
熊雪
余瑷砾
XIONG Xue;YU Aili(Department Of Cardiovascular Medicine,the Seventh People＇s Hospital of Chengdu City,Sichuan Province 610000)
出处
《医学理论与实践》
2018年第22期3319-3321,共3页
The Journal of Medical Theory and Practice
关键词
阿托伐他汀
老年冠心病
经皮冠状动脉介入治疗
再狭窄
炎症因子
Atorvastatin
Elderly coronary heart disease patients
Percutaneous coronary intervention
Restenosis
hfflammation factors
